Transoral Incisionless Fundoplication effective in reducing gastroesophageal reflux disease symptoms

Transoral Incisionless Fundoplication (TIF) utilizing the EsophyX device was found to be safe and effective in decreasing atypical gastroesophageal reflux disease symptoms at 6- and 12-month follow-up, says an article published in Gastrointestinal Endoscopy Journal.

The EsophyX device was used in the first transoral incisionless fundoplication (TIF) treatment in 2005. More than 17 000 surgeries have been finished since then. Since the early iterations of this process were the subject of the original European experience and publications, the EsophyX device was approved by the Food and Drug Administration in the United States in 2007. A minimally invasive endoscopic fundoplication approach is transoral incisionless fundoplication employing the EsophyX device. This study was carried out by Muhammad Haseeb and colleagues to evaluate the effectiveness of TIF for atypical GERD symptoms in individuals with chronic or resistant GERD.

Four important databases were thoroughly searched. The Reflux Symptom Index (RSI), a validated symptom questionnaire, was used in all first research examining atypical GERD. Pre-TIF and post-TIF RSI scores were evaluated at 6- and 12-month follow-up. Additionally, information on patient satisfaction, proton pump inhibitor (PPI) usage, adverse events, and technical success rate was gathered. Only TIF 2.0 and TIF with concurrent hiatal hernia repair (cTIF), which are presently used in practice utilizing the EsophyX device, were covered in the evaluation.